This concept parallels estrogen receptor 1 (ESR1) mutations in HR-positive breast cancer, in which approximately 20% of patients develop acquired mutations following endocrine therapy, whereas 1–5% harbor de novo ESR1 mutations at baseline. This evidence concerns the gene ESR1 and breast carcinoma.